Case series of long-term macrolide therapy effect on eosinophil count in COPD

R. Asciak (Oxford, United Kingdom)

Source: International Congress 2017 – COPD management
Session: COPD management
Session type: Thematic Poster
Number: 1058
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
R. Asciak (Oxford, United Kingdom). Case series of long-term macrolide therapy effect on eosinophil count in COPD. 1058

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Effect of COPD exacerbations on early lung function decline under maintenance therapy: blood eosinophil count asbiomarker
Source: International Congress 2019 – Eosinophils and FeNO in airway diseases
Year: 2019




Minimal effect of inhaled corticosteroids (ICS) on blood eosinophil count in steroid-naïve COPD patients
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015


Association between blood eosinophil count and exacerbation risk in patients with asthma receiving medium- or high-dosage inhaled corticosteroids
Source: International Congress 2017 – Biomarker-based asthma control
Year: 2017


Cost-effectiveness of single-inhaler triple therapy for chronic obstructive pulmonary disease treatment by baseline blood eosinophil count: IMPACT trial
Source: Virtual Congress 2021 – Difficult decisions on expected outcomes: availability of hospital resources and improvement of treatment adherence
Year: 2021



Impact on steroid dosing after introducing sputum eosinophils count into a severe asthma clinic
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009


The impact of high eosinophil count on hospitalizations in COPD patients
Source: International Congress 2018 – Biomarkers of COPD
Year: 2018

Increased platelet reactivity during acute exacerbations of COPD, irrespective of antiplatelet therapy
Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD
Year: 2015

Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis
Source: Eur Respir J 2014; 44: 789-791
Year: 2014


Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD
Source: Eur Respir J, 55 (5) 1902119; 10.1183/13993003.02119-2019
Year: 2020



Association between blood eosinophil count and risk of exacerbations in patients with COPD
Source: International Congress 2017 – Biomarker-based asthma control
Year: 2017


Eosinophil counts as a predictor of future COPD exacerbations in the DYNAGITO trial
Source: International Congress 2019 – Eosinophils and FeNO in airway diseases
Year: 2019




Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations
Source: Eur Respir J 2006; 27: 483-494
Year: 2006



One year monitoring of children with bronchial asthma and other allergic diseases treated with inhaled corticosteroids vs cromoglycates with serum ECP (S-ECP), FEV1, total IgE and blood eosinophil count - the influence of different therapy
Source: Eur Respir J 2002; 20: Suppl. 38, 432s
Year: 2002

Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study
Source: Eur Respir J, 51 (5) 1702523; 10.1183/13993003.02523-2017
Year: 2018



Blood eosinophil (EOS) count, exacerbation rate and response to roflumilast in patients with severe COPD
Source: International Congress 2017 – What is new in COPD management and prognosis: findings from large studies?
Year: 2017


Use of Inhaled corticosteroid (ICS)-containing regimen for COPD patients with high or low blood eosinophilia: A meta-analysis
Source: International Congress 2018 – Clinical determinants and biomarkers of COPD
Year: 2018

Immunomodulatory treatment of severe persistent asthma with interferon-αcon-1 (IFN-αcon-1). Effect on the clinical course of oral corticosteroid dose and eosinophil numbers
Source: Annual Congress 2003 - Modulation of bronchial hyperreactivity and immune response in the airways
Year: 2003


Peripheral blood eosinophil counts in COPD patients and its relationship with prescription of inhaled corticosteroid in real world setting in Japan.
Source: International Congress 2017 – Airway disease and exacerbations
Year: 2017

Circulating eosinophil levels do not predict severe exacerbations in COPD: a retrospective study
Source: ERJ Open Res, 4 (3) 00022-2018; 10.1183/23120541.00022-2018
Year: 2018



The adherence to inhaled drugs in COPD patients: Effect on survival
Source: International Congress 2015 – Treatment and control of respiratory disease
Year: 2015